摘要
目的:观察布地奈德雾化吸入联合阿奇霉素治疗支原体肺炎患儿的效果。方法:选取2019年1月至2020年12月该院收治的86例小儿肺炎支原体感染患儿进行前瞻性研究,按照随机数字表法分为对照组和观察组各43例。对照组给予阿奇霉素治疗,观察组在对照组基础上联合布地奈德雾化吸入治疗。比较两组临床疗效,临床症状消失时间,血清免疫球蛋白[免疫球蛋白(Ig)G、IgA、IgM]水平,炎性因子[超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)]水平及不良反应发生率。结果:观察组治疗总有效率为93.02%,高于对照组的74.42%,差异有统计学意义(P<0.05);治疗后,观察组咳嗽、发热、肺啰音、胸闷等症状消失时间均短于对照组,差异有统计学意义(P<0.05);观察组IgG、IgA、IgM水平均高于对照组,差异有统计学意义(P<0.05);观察组IL-6、hs-CRP水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:布地奈德雾化吸入联合阿奇霉素治疗支原体肺炎患儿,可提高治疗总有效率和血清免疫球蛋白水平,缩短症状消失时间,降低炎性因子水平,其效果优于单纯阿奇霉素治疗。
Objective:To observe effects of Budesonide atomization inhalation combined with Azithromycin the treatment of children with mycoplasma pneumonia.Methods:86 children with Mycoplasma pneumoniae infection admitted to the hospital from January 2019 to December 2020 were selected for a prospective study,and were divided into control group and observation group according to the random number table method,43 cases in each group.The control group was given Azithromycin therapy,while the observation group was given Budesonide atomization inhalation therapy on the basis of that of the control group.The clinical efficacy,the clinical symptoms disappearance time,the serum immunoglobulin levels[immunoglobulin(Ig)G,IgA,IgM],the inflammatory factor levels[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)],and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 93.02%,which was higher than 74.42%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the disappearance time of cough,fever,pulmonary rales,chest tightness and other symptoms in the observation group were shorter than those in the control group,and the differences were statistically significant(P<0.05).The levels of IgG,IgA and IgM in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of IL-6 and hs-CRP in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Budesonide atomization inhalation combined with Azithromycin in the treatment of the children with mycoplasma pneumonia can improve the total effective rate and serum immunoglobulin levels,shorten the symptom disappearance time,and reduce the levels of inflammatory factors Moreover,it is superior to single
作者
聂上清
NIE Shangqing(The Second Department of Pediatrics of Guangshan County People’s Hospital,Xinyang 465400 Henan,China)
出处
《中国民康医学》
2022年第17期48-50,共3页
Medical Journal of Chinese People’s Health
关键词
布地奈德
雾化
阿奇霉素
支原体肺炎
炎性因子
免疫功能
不良反应
Budesonide
Atomization
Azithromycin
Mycoplasma pneumonia
Inflammatory factor
Immune function
Adverse reaction
